Analysts Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Price Target at $4.94

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given a consensus recommendation of “Hold” by the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $4.94.

A number of research analysts recently issued reports on the company. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. D. Boral Capital reissued a “buy” rating and issued a $12.00 target price on shares of Carisma Therapeutics in a research note on Monday, January 13th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th.

Carisma Therapeutics Stock Performance

Shares of CARM stock opened at $0.39 on Friday. The stock has a 50 day moving average price of $0.44 and a two-hundred day moving average price of $0.68. Carisma Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $2.39. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market capitalization of $16.08 million, a P/E ratio of -0.25 and a beta of 1.55.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CARM. Barclays PLC increased its position in Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Wexford Capital LP grew its position in Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after buying an additional 24,600 shares during the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.